Monthly Archives: March 2015

Paul Puey: How Bitcoin Will Revolutionize Mobile Payments – LA Bitcoin Meetup 2.25.15 – Video

Posted on by


Paul Puey: How Bitcoin Will Revolutionize Mobile Payments - LA Bitcoin Meetup 2.25.15
Paul Puey, CEO of Airbitz (https://airbitz.co) joined us at the Los Angeles Bitcoin Meetup on February 25 at Gem HQ for an insightful discussion about Bitcoin and the mobile payments industry...

By: Gem

Read this article:

Paul Puey: How Bitcoin Will Revolutionize Mobile Payments - LA Bitcoin Meetup 2.25.15 - Video

Airbitz 2FA – Worlds First One-Touch 2 Factor Authentication – Video

Posted on by


Airbitz 2FA - Worlds First One-Touch 2 Factor Authentication
Airbitz bitcoin wallet introduces the world #39;s first 1 touch two factor authentication. You can now lock your account to a device with a single touch. Accessing your account from additional...

By: Airbitz Bitcoin Wallet

See the original post:

Airbitz 2FA - Worlds First One-Touch 2 Factor Authentication - Video

Comets Announce Roster Moves

Posted on by

March 20, 2015 - American Hockey League (AHL) Utica Comets Utica Comets Director of Hockey Operations Pat Conacher announced today that the team has signed defenseman Ben Hutton to a professional tryout contract (PTO), and that goaltender Pat Nagle has been released from his PTO. Also, the Vancouver Canucks have reassigned goaltender Joe Cannata to the Comets from the Ontario Reign of the ECHL.

Hutton, 21, recorded 21 points (9 goals, 12assists) and 14 penalty minutes with the University of Maine this season. In 108 career total NCAA games for the Black Bears, Hutton notched 65 points (28 goals, 37 assists) and logged 40 penalty minutes. Hutton was named a Second Team All-American, and to the Hockey East First Team and was also the recipient of the Bob Monahan Award (top defenceman in New England) following a career season in 2013.14.

The 6'3" 200-pound native of Prescott, Ontario was selected by Vancouver 147th overall in the 2012 NHL Entry Draft.

Nagle, 27, appeared in one game for the Comets where he stopped 25 of the Syracuse Crunch's 28 shots in a loss. In 28 games with the ECHL's Fort Wayne Komets this season Nagle owns a 2.35 GAA alongside a 0.910 save percentage and a 20-5-1-1 record.

Cannata, 25, currently ranks third in ECHL goaltenders in goals-against average (2.02) and in save percentage (0.927). He has allowed just 42 goals in 21 games with Ontario and has posted a 12-6-0-2 record with a shutout. He was the starting goalie in the ECHL All-Star game.

The Wakefield, Mass. native appeared in 28 games with the Comets last season and went 11-12-1-3 with a 2.83 goals-against average and a 0.907 save percentage. He finished the season strong by winning seven of his last nine starts with just a 2.08 goals-against average.

A sixth-round selection (173rd overall) of the Canucks in the 2009 NHL Entry Draft, Cannata played four years at Merrimack College from 2008-12, where he appeared in 122 career games posting an overall record of 59-46-16 with seven shutouts, a 2.47 goals-against average and a save percentage of .915.

For a complete schedule of Utica Comets games, as well as ticketing information, visit http://www.uticacomets.com.

Discuss this story on the American Hockey League message board... Digg this story Add to Del.icio.us

Continue reading here:

Comets Announce Roster Moves

Comets Braithwaite Suspended Indefinitely

Posted on by

March 19, 2015 - Major Arena Soccer League (MASL) The Major Arena Soccer League today issued a statement and announced suspensions following events that took place surrounding Game 2 of the Eastern Conference Finals Sunday in Independence, Missouri.

Missouri Comets defender Andre Braithwaite will be suspended indefinitely by the league for his head-butt as teams were shaking hands after the game. He can apply for reinstatement following the 2015/16 season. The Comets released him immediately following the game.

Comets defender Brian Harris, who was given a red card for a reckless slide tackle with 12 seconds remaining in the game, will be suspended for the first three games of the 2015/16 season.

Comets defender John Sosa, who was given a red card for verbal abuse, will be suspended for one game to be served at the beginning of the 2015/16 season.

"The MASL cannot condone physical play or actions where the intention is to cause harm to other players," said MASL Commissioner Kevin Milliken. "These incidents have taken the spotlight off what was a competitive series between two of the league's top teams, and marred what had been an outstanding season by the Missouri Comets."

Following Game 2 of the Baltimore/Missouri series there was an implication by a coach of improper communication between an owner and a referee prior to the game. After reviewing the allegations and watching the video of the game, the league did not find any merit to the allegations. Behavior of others surrounding this game is still being investigated.

Discuss this story on the Major Arena Soccer League message board... Digg this story Add to Del.icio.us

Read the original post:

Comets Braithwaite Suspended Indefinitely

March 28 Is Military Night at the Aud

Posted on by

March 20, 2015 - American Hockey League (AHL) Utica Comets The Utica Comets will honor the men and women who have served, and continue to serve, our country with Military Night on Saturday, March 28. It is a night dedicated to raising funds and awareness for the Veteran's Outreach Center.

The Comets will wear special blue camouflage sweaters that will be sold during a live auction immediately following Saturday night's game.

The Comets are also offering military service members, including veterans, a special $12 ticket for any available seat to Saturday's game, against the Rochester Americans, when they show a valid military ID at the box office.

The National Guard will have a weapons display and games on the concourse for fans to compete and learn more about these branches of the military.

The UCD/ CNYVOC was formed to provide and conduct charitable, educational, social service, and housing services for veterans in need. CNYVOC is in the process of creating a resourceful, one stop facility in Utica for veterans residing throughout Central New York. When complete this facility would offer, among other services, transitional housing for homeless veterans with permanent housing for disabled and elderly veterans, plus a wide variety of other services.

Discuss this story on the American Hockey League message board... Digg this story Add to Del.icio.us

Follow this link:

March 28 Is Military Night at the Aud

New Novartis data show more Cosentyx-treated psoriasis patients achieved clear or almost clear skin (PASI 90 …

Posted on by

EAST HANOVER, N.J., March 20, 2015 /PRNewswire/ --Novartis today announced results from the CLEAR study demonstrating Cosentyx (secukinumab) improved skin clearance at Week 16 in significantly more moderate-to-severe plaque psoriasis patients compared to Stelara* (ustekinumab), a widely used biologic. The detailed findings were presented in a late-breaking research session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult patients with moderate-to-severe plaque psoriasis.

"As a clinician I have seen first-hand the impact that moderate-to-severe plaque psoriasis can have on patients' lives and the frustration some feel when they are unable to achieve clear or near clear skin," said Andrew Blauvelt, MD, MBA, President of the Oregon Medical Research Center and lead study investigator. "The CLEAR data are an important step forward for clinicians and patients as they demonstrate Cosentyx compares favorably to Stelara, a widely used biologic."

In this Phase IIIb study, Cosentyx met the primary endpoint of superiority to Stelara as assessed by the Psoriasis Area Severity Index (PASI) 90 response, known as clear to almost clear skin, at Week 16 (79.0% vs. 57.6%, P<0.0001). The secondary endpoint found 50% of Cosentyx patients achieved PASI 75 at Week 4 compared to 20.6% of Stelara patients (P<0.0001).

PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body. Treatment efficacy is assessed by the reduction of the score from baseline (i.e., a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90). PASI 90 is a higher standard of skin clearance compared to PASI 75.

In an exploratory analysis, completely clear skin (PASI 100) at Week 16 was achieved by significantly more patients treated with Cosentyx than those receiving Stelara (44.3% vs. 28.4%).

"Helping psoriasis sufferers achieve clear skin remains the goal for both patients and their physicians, yet many patients still do not achieve this," said Christi Shaw, US Country Head, President of Novartis Corporation and Novartis Pharmaceuticals Corporation. "The findings from the CLEAR study demonstrate that Cosentyx helps a majority of patients relieve the thick, red, scaling and extensive plaques that are common in those living with psoriasis. The data reinforce the importance of Cosentyx as a beneficial new treatment option, offering hope to psoriasis patients so they can take control of this often isolating disease."

The safety profile of Cosentyx was comparable to Stelara and consistent with previously reported Phase III clinical trials for Cosentyx. In the study, the most common adverse events (AEs) in the Cosentyx-treatment arm were headache (7.8%), nasopharyngitis (6.9%), diarrhea and fatigue (4.2% each), and arthralgia (3.9%). The most common AEs in the Stelara-treatment arm were nasopharyngitis (10.1%), headache (8.0%), arthralgia (4.2%), diarrhea (3.6%), and fatigue (2.7%). Infections and infestations were comparable between the Cosentyx and Stelara treatment groups (29.3% and 25.3%, respectively). Non-fatal serious adverse events in both treatment groups were the same (3%). No deaths have been reported, to date.

About the CLEAR studyCLEAR (Comparison to assessLong-termEfficacy, sAfety and toleRability of secukinumab vs. ustekinumab), a 52-week, multicenter, randomized, double-blind study, is a head-to-head Phase IIIb study initiated with Cosentyx, and compares the efficacy, long-term safety and tolerability of Cosentyx (secukinumab) versus Stelara (ustekinumab), in patients with moderate-to-severe plaque psoriasis. Twenty-four countries across North America, Europe, Asia and Australiaparticipated in the single study, with enrollment reaching 679 patients in record time.

The primary endpoint measured at Week 16 is PASI 90. PASI 90 is considered a more robust measure of the extent of skin clearance compared to the standard efficacy measures used in most psoriasis clinical studies, such as PASI 75. Additionally the secondary endpoint measured at Week 4 is PASI 75. PASI 100 at Week 16 was one of the exploratory endpoints. Week 52 data will follow in due course.

About Cosentyx (secukinumab) and interleukin-17A (IL-17A) Cosentyx (secukinumab, previously known as AIN457) is a human monoclonal antibody (mAb) that selectively binds to interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. It is the first IL-17A antagonist approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy).

Read the original here:

New Novartis data show more Cosentyx-treated psoriasis patients achieved clear or almost clear skin (PASI 90 ...